International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2023

Lumanity is proud to be taking part at ISPOR Europe 2023, the leading health economics and outcomes research (HEOR) conference. ISPOR brings together global HEOR leaders, policy makers, regulators, researchers, academics, payers, patients, and patient groups under one roof to network and discuss this year’s topic ‘HEOR at the Nexus of Policy and Science’.

What we’re talking about at ISPOR 

With seismic policy changes on the horizon and increased focus on delivering value, this year we are encouraging pharmaceutical manufacturers to get ahead of the curve. We can help you avoid pitfalls and overcome obstacles by identifying them early and strategizing solutions for successful outcomes.

Continue reading to find out why time is of the essence and early planning is essential. Speak to our team at ISPOR to find out how we can help.

Meet with Our Experts at Booth C2-005

Stop by our booth (C2-005) to meet our experts in person. If you are interested in scheduling a meeting with one of our experts, please don’t hesitate to reach out using the link below.

Short Course

Sunday, 12 November | 08:00-12:00

Felicity Lamrock, Gianluca Baio, Howard Thom, Rose Hart.

Health Economic Modeling in R: A Hands-on Introduction

Lumanity’s Rose Hart is a presenter in this highly practical course. The course outlines the computational and transparency advantages of using R, for those used to health economic modelling using Microsoft Excel. This course explores the use of R for health economic modelling in the context of health economics and outcomes research (HEOR) and faculty will guide the participants through practical examples of HEOR.

Breakout Session

Monday, 13 November | 17:00 – 18:00

Moderator: Josie Godfrey
Panelists: Ron Akehurst, Fleur Chandler, Jill Carlton.

Measuring Health Related Quality of Life in Pediatric Life Limiting Progressive Diseases. Whose Perspective Are We Measuring?

Lumanity’s Ron Akehurst joins the panel discussing the different approaches to including HRQoL in paediatric life-limiting conditions in HTA. Which perspective (proxy, patient or population) is most useful to decision-making, how to take into account the impact of disease progression over a lifetime and how best to interpret the results of HRQoL measures in clinical trials.

HTA Case Study

Tuesday, 14 November | 10:15 – 11:15

Matthijsse S, Akehurst R, Gladwell D, Wasem J.

HTA Reforms in Germany: Implications for Pharmaceutical Pricing and Reimbursement in Germany and the EU

Lumanity experts, joined by former chairperson of the Arzneimittelmarkt-Neuordnungsgesetz (AMNOG) Drug Price Arbitration Board Juergen Wasem, explore the most significant implications for pharmaceutical pricing and reimbursement in Germany following the approval of the cost-containment law and how the new bill interacts with the new European Regulation on HTA.

Posters

Monday, 13 November – Poster Session 1 | 10:30 – 13:30

Behavioural Structured Expert Elicitation: A Case Study to Inform Hospitalisation Due to Respiratory Syncytial Virus in the UK
Schurer M, Murphy L, Horscroft J, Chetty M, Hudson R.

Clinical Outcomes of Patients with Relapsed/Refractory Large B-Cell Lymphoma Receiving Second-Line Therapy in England: A Multicenter, Retrospective, Real-World Study
Fox CP, Sugrue D, Toron F, Tyas E, Cooper M, Richards J, Williams P.

Cost-Effectiveness Analysis of Pemigatinib for the Treatment of Adult Patients with Locally Advanced or Metastatic Cholangiocarcinoma with a FGFR2 Fusion or Rearrangement That Have Progressed After Systemic Therapy in Greece
Tzanetakos C, Psarra M, Batsi M, Patterson K, Vostitsanou Z, Gourzoulidis G.

Health-Related Quality of Life and Its Drivers for Patients Living with Cystic Fibrosis in Five Key European Countries: A Systematic Review
Verma R, Telukuntla V, Ahuja A.

Hybrid Closed Loops – A Cost-Effective Future for Type 1 Diabetes Standard of Care? An Update to the TA10845 Economic SLR
Brown L, Jindal S, Smith M.

The Burden of Illness of Vasomotor Symptoms Associated with Menopause
Malacan J, Rosa Bolling K, Haberland C, Gaianu L, Smith N, Woods M, Smith M.

Use of Clinical Outcome Assessments in Health Technology Appraisals for Rare Disease Indications: A Review of UK, US, and Canadian Submissions
Jones E, Hyman J, Weijers L, Johnson N.

Monday, 13 November – Poster Session 2 | 15:30 – 18:30

Combining Causal Inference and Within-Trial Economic Evaluation Methods to Assess the Cost-Effectiveness of a Mental Health Service Using Real-World Data: The Quasi-Experimental Adapt Study
Franklin M, Porter A, De Vocht F, Kearns B, Latimer N, Hernandez M, Young T, Kidger J.

Economic Evaluation and Budget Impact of ERTs in Patients with Pompe Disease – a Systematic Literature Review
Jindal S, Sharma A, Mahajan K, Saharia P, Mohan V.

Economic Evaluations of Medical Devices Used in the Treatment of Breast Cancer: A Systematic Review
Madan T, Rohilla A, Taneja A.

Estimating Health-Related Quality of Life in Fabry Disease for Patients Treated with Enzyme-Replacement Therapy in the BALANCE Randomized Controlled Trial
Lee B, Hemstock M, Stevenson A, Stork R, Azimpour K.

Menopause: More Than Just Vasomotor Symptoms
Malacan J, Rosa Bolling K, Haberland C, Gaianu L, Smith N, Woods M, Smith M.

Tuesday, 14 November – Poster Session 3 | 10:30 – 13:30

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy, With or Without Bevacizumab for the First-Line Treatment of PD-L1-Positive Patients With Persistent, Recurrent, or Metastatic Cervical Cancer in France
Ray-Coquard I, Pautier P, Muston D, Monberg MJ, Swami S, Chaker O, Bensimon L, Lange S, Kulakova M, Durand Zaleski I, Marié L.

Economic Burden of Wilson’s Disease: A Systematic Review
Garg J, Mandal A, Khurana IS, Ahuja A.

Economic Evaluation of PD-1 Blockers in Merkel Cell Carcinoma: A Systematic Literature Review
Ghoshal D, Madan T, Taneja A.

Impact in Health Outcomes of PD-(L)1 Inhibitors to Treat Early Stages Cancers in Switzerland
Favre-Bulle A, Sönmez D, Stankovic M, Neves C, Mantaian T, Frei C, Schaefer S, Flori M, Aguiar-Ibáñez R.

Methods for incorporating external evidence: a comparison of their impact on extrapolations and uncertainty estimates using a melanoma case-study
Kearns B, Wolff H, Kilvert H.

Tuesday, 14 November – Poster Session 4 | 15:30 – 18:30

A Scoping Review of Health Technology Assessment Agency (HTA) and Health Economic (HE) Modelling Guidelines for Identification of Health Economic Model Inputs
Lister J, Paisley S, Tappenden P, Carroll C.

Economic Burden of Cystic Fibrosis in Five Key European Countries: A systematic Review
Verma R, Telukuntla V, Ahuja A.

Health-Related Quality of Life and Its Drivers for Patients Living with Glioblastoma in Europe: A Systematic Review
Telukuntla V, Azad M, Verma R, Ahuja A.

Impact of Roflumilast Foam 0.3% on Patient-Reported Quality of Life in Seborrheic Dermatitis: An Analysis of Stratum Data for Patients Unresponsive or Intolerant to Topical Corticosteroids
Chu DH, Lee J, Stephenson B, Bannister B, Hickey C, Westley T, Zirwas M.

Patient Voice in Smc Technology Appraisals for Orphan and Ultra-Orphan Diseases
Gupta A, Jindal S, Mahajan K, Sharma A, Saharia P.

Wednesday, 15 November – Poster Session 5 | 09:00 – 11:30

Associations of Sex and Race with Relative Efficacy in Clinical Trials
Zhao P, Qu T, Shi S.

Cost-Effectiveness Analysis of Pembrolizumab for First-Line Treatment in Patients With Persistent, Recurrent, and Metastatic Cervical Cancer in the United States: Results From the Final Analysis of Trial
Swami S, Hale O, Thornton I, Muston D, Monberg MJ, Monk BJ.

Economic Evaluation of Focal Therapy Used in the Treatment of Prostate Cancer: A Systematic Review
Garg J, Madan T, Taneja A.

Identification of Health State Utility Values for Health Economic Models: Empirical Testing of Alternative Search Methods
Lister J, Paisley S, Tappenden P, Carroll C.

NICE Technology Appraisals Based on Single-Arm Trials in 2022 – What Can We Learn from Them?
Guerra Primo L, Matthijsse S, Westley T.